消除丙型肝炎面临的机遇与挑战

摘要/Abstract

摘要： 丙型肝炎是一种全身性疾病,不仅有肝脏损伤,也能引起多种肝外疾病。直接抗病毒药物治疗是国际指南推荐的丙型肝炎病毒血症治疗方案,其优点在于治疗丙型肝炎患者能够获得良好的持续病毒学应答率,且药物不良反应少,治疗疗程短。实现2030年消除丙型肝炎的公共卫生危害目标仍有许多障碍,应当从加强丙型肝炎病毒感染者筛查、提供充分的治疗机会、切断疾病传播链以及对易感人群的保护和预防着力。对普通人群进行广泛筛查,早诊断、积极使用新研发的直接抗病毒药物治疗,将进一步减少丙型肝炎病毒感染引起的肝炎和相关并发症以及降低丙型肝炎相关的死亡风险。

关键词: 丙型肝炎, 直接抗病毒药物, 持续病毒学应答, 消除公共卫生危害

廖敏君, 饶慧瑛. 消除丙型肝炎面临的机遇与挑战[J]. 肝脏, 2023, 28(10): 1143-1145.

参考文献

[1] Lee HW, Lee H, Kim BK, et al. Cost-effectiveness of chronic hepatitis C screening and treatment[J]. Clin Mol Hepatol,2022,28:164-173.
[2] Thein HH, Yi Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression[J]. Hepatolog,y 2008,48:418-431.
[3] Westbrook RH, Dusheiko G. Natural history of hepatitis C[J]. J Hepatol,2014,61:S58-S68.
[4] Wiese M, Berr F, Lafrenz M, et al. Low frequency of cirrhosis in a hepatitis C(genotype 1b) single-source outbreak in germany: A 20-year multicenter study[J]. Hepatology, 2000,32:91-96.
[5] Taha G, Ezra L, Abu-Freha N. Hepatitis C Elimination: Opportunities and Challenges in 2023[J]. Viruses,2023,15(7):1413.
[6] Kåberg M, Weiland O. Hepatitis C elimination-Macro-elimination[J]. Liver Int,2020,40:61-66.
[7] Wang AE, Hsieh E, Turner BJ, et al. Integrating Management of Hepatitis C Infection into Primary Care: the Key to Hepatitis C Elimination Efforts[J]. J Gen Int Med, 2022,37:3435-3443.
[8] Pawlotsky JM, Negro F, Aghemo A, et al. EASL recommendations on treatment of hepatitis C: Final update of the series[J]. J Hepatol,2020,73:1170-1218.
[9] Poynard T, Moussalli J, Munteanu M, et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C[J]. J Hepatol,2013;59:675-683.
[10] van der Meer AJ WH, Feld JJ, Dufour JF, et al. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population[J]. JAMA,2014,312(18):1927-1928.
[11] Li DK, Ren Y, Fierer DS, et al. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study[J]. Hepatology,2018,67:2244-2253.
[12] Chang KC, Hung CH, Lu SN, et al. A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy[J]. J Antimicrob Chemother,2012,67:2766-2772.
[13] Huang CF, Yeh ML, Tsai PC, et al. Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication[J]. J Hepatol,2014,61:67-74.
[14] Pereira GH, Peixoto HR, Giusti ML, et al. Long-term survival and clinical outcomes following direct-acting antiviral (DAA) treatment in HCV decompensated cirrhosis in Brazil: a real-world study[J]. Brazil J Infect Dis,2022,26(5):102697.
[15] Di Marco L, La Mantia C, Di Marco V. Hepatitis C: Standard of Treatment and What to Do for Global Elimination[J]. Viruses,2022,14(3):505.
[16] Schillie SWC, Osborne M, Wesolowski L, et al. CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020[J]. MMWR Recomm Rep,2020, 69(2):1-17.
[17] Kondili LA, Andreoni M, Alberti A, et al. Estimated prevalence of undiagnosed HCV infected individuals in Italy: A mathematical model by route of transmission and fibrosis progression[J]. Epidemics,2021,34:100442.
[18] Panel AIHG. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection[J]. Clin Infect Dis,2018, 67(10):1477-1492.
[19] Calvaruso V, Craxì A. Hepatic benefits of HCV cure. J Hepatol,2020,73:1548-1556.
[20] Hagan LM, Kasradze A, Salyer SJ, et al. Hepatitis C prevalence and risk factors in Georgia, 2015: setting a baseline for elimination[J]. BMC Public Health,2019,19(Suppl 3):480.
[21] Pierce BG, Keck ZY, Foung SKH. Viral evasion and challenges of hepatitis C virus vaccine development[J]. Curr Opin Virol,2016,20:55-63.